• •To determine the highest tolerated dose of GSK1120212 when given for 21 days using blood values of study drug and reported side-effects.
  

• •To determine safety and cancer marker levels in the blood/tumors for study drug after single- and repeat-doses for for 21 days and to obseve tumor responses.
  
• GSK1120212 PK parameters following single- and repeat-dose administration of GSK1120212, including AUC(0-∞), AUC(0-τ), Cmax, tmax, t½ (terminal phase and/or effective half-life), accumulation ratio, and time invariance.responses.
  
• Change in p-ERK and other markers in tumor biopsies.
  
• Tumor response as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
  
• Correlation between PK, PD, and clinical endpoints
  

Inclusion Criteria:

• Written informed consent provided.
• 18 years old or older.
• Histologically or cytologically confirmed diagnosis of solid tumor malignancy or lymphoma that is not responsive to standard therapies or for which there is no approved or curative therapy.
• Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) scale.
• Able to swallow and retain oral medication.
• Male subjects must agree to use one of the contraception methods listed. This criterion must be followed from the time of the first dose of study medication until four weeks after the last dose of study medication. However, the Sponsor advises that contraception be used for a total of 16 weeks following the last dose (based on the lifecycle of sperm).
• A female subject is eligible to participate if she is of:
• Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/mL and estradiol < 40 pg/mL (<140 pmol/L) is confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods in Section 8.1 if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least two to four weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.
• Child-bearing potential and agrees to use one of the contraception methods listed in Section 8.1 for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until four weeks after the last dose of study medication.
• Note: Oral contraceptives are not reliable due to potential drug-drug interaction.
• Serum calcium level < 1x upper limit of normal (ULN).
• Serum inorganic phosphorus level < 1x ULN.
• Adequate organ system function as defined in Table 6. (Laboratory values just outside the normal reference range may be included if in the view of the investigator and medical monitor, these findings will not interfere with the study or introduce additional risk factors.)

Exclusion Criteria:

• Currently receiving cancer therapy (chemotherapy, radiation therapy, immuno-therapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization).
• Use of an investigational anti-cancer drug within 28 days or five half-lives, whichever is longer, preceding the first dose of GSK1120212.
• Previous treatment with a MEK inhibitor or BRAF inhibitor.
• Current use of a prohibited medication or requires any of these medications during treatment with GSK1120212.
• Current use of warfarin.
• Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs.
• Any major surgery, radiotherapy, or immunotherapy within the last four weeks. Chemotherapy regimens with delayed toxicity within the last four weeks (six weeks for prior nitrosourea or mitomycin C).